<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR25">
 <label>25.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Lebwohl</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Rivera-Oyola</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Murrell</surname>
    <given-names>DF</given-names>
   </name>
  </person-group>
  <article-title>Should biologics for psoriasis be interrupted in the era of COVID-19?</article-title>
  <source>J Am Acad Dermatol.</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1016/j.jaad.2020.03.031</pub-id>
  <?supplied-pmid 32199889?>
  <pub-id pub-id-type="pmid">32199889</pub-id>
 </element-citation>
</ref>
